Antisense Therapeutics Limited (ASX: ANP) is a biopharmaceutical company which is primarily into the discovery and development of drugs. The company has an objective to create, develop and commercialize novel antisense pharmaceuticals patients with diseases like includes Duchenne Muscular Dystrophy, Multiple Sclerosis, and Acromegaly. [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]
Duchenne Muscular Dystrophy (DMD) makes muscles weaker and less flexible over time. It is caused primarily from the flaws in genes, which controls the muscle movements and keep the muscles healthy. This gene linked disease can affect one in 3600 to 6000 live male births. The transformation in the dystrophin gene since causes Duchenne Muscular Dystrophy since it reduces or causes absence of the dystrophin protein. Children affected by the Duchenne Muscular Dystrophy have dystrophin-deficient muscles and are they are likely to be influenced by the contraction induced injury to the muscle. This triggers the immune system which aggravates the muscle damage as mentioned by the Director of the FDA CDER in a publication.
On 18 January 2019, the company has announced that five patients have been enrolled in the nine- patient Phase II clinical trial of its immunomodulatory therapy for Duchenne Muscular Dystrophy. Four patients have been given the dose with ATL1102 in the trial with a 5th screened patient having met the eligibility criteria for the trial; however, their dosing will commence early February. No adverse severe safety-related events have been noticed and reported to date.
The clinical details of the trial are included on prominent US-based DMD advocacy group website. Parent Project Muscular Dystrophy, the US-based Duchenne Muscular Dystrophy advocacy group has secured significant money for funding and winning FDA approvals. They have recently incorporated details on the ATL1102 for DMD trial. Their efforts are focussed on advance care and treatments for Duchenne Muscular Dystrophy by capitalizing on federal resources of US, building partnerships and creating several regulatory procedures and infrastructures.
The trial, however, is completed now, with 50% patients enrolled and is on track for all nine patients to have been enrolled with their dosing scheduled to be completed in Q3 FY19 with the trial results to come after that. Since this is an open-label study, there is a possibility for earlier study readouts on preliminary data in a sufficient number of patients.
Now let us quickly look at the Antisense Therapeutics Limited’s stock, and the returns it has posted over the last few months. It is trading at a price of $0.034 and increased by a whopping 27.429% approximately during the day’s trade, with a market capitalization of ~$10.41 million. The stock opened at $0.032 which is also the day high of the stock and posted a day low of $0.028. The company has yielded a YTD return of 7.69% and posted returns of 12.0%, -54.84% and -3.45% over the last six months, three months and one-month period, respectively. It has a 52-week high price of $0.094 and a 52-week low of $0.017, with an average volume of ~4.71 million approximately.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.